文献速递瓣膜外科

经心尖J-Valve瓣膜系统治疗主动脉瓣疾病的临床结果

Transapical Transcatheter Valve Replacement Using J-Valve for Aortic Valve Diseases.
PubMed 文献 · Ann Thorac Surg · 2020-11-27

本研究回顾了2018年1月至2019年8月接受经心尖J-Valve瓣膜系统治疗的23例主动脉瓣疾病患者,涵盖主动脉瓣狭窄、单纯主动脉瓣反流及瓣中瓣病例。技术成功率为91.3%(21/23),术后死亡1例(4.3%,1/22),无中重度瓣周漏,未需永久起搏器植入。结论认为该系统的优势在于适用于单纯主动脉瓣反流患者。

要点

  • J-Valve系统适用于主动脉瓣狭窄和单纯主动脉瓣反流,技术成功率91.3%。
  • 术后死亡率4.3%,无中重度瓣周漏,无永久起搏器植入。
  • 该系统优势在于可治疗单纯主动脉瓣反流患者。

核心结论

  • 经心尖J-Valve瓣膜系统治疗主动脉瓣疾病有效,尤其适用于单纯主动脉瓣反流患者。

研究设计与样本

  • 回顾性单中心研究,纳入2018年1月至2019年8月23例接受经心尖J-Valve瓣膜系统治疗的主动脉瓣疾病患者。

主要发现

  • 技术成功率为91.3%(21/23),1例转为开放手术,1例接受术中瓣中瓣。
  • 术后1例死于心源性休克,死亡率为4.3%(1/22)。
  • 术后1例发生卒中并恢复良好,无患者需永久起搏器植入。
  • 随访期间1例死于急性心脏病发作,无中重度瓣周漏。
  • 术前STS平均评分8.9%,EuroSCORE平均评分8.7%。

临床怎么用

  • 对于外科高危、外周血管条件差、单纯主动脉瓣反流或复杂瓣中瓣患者,可考虑经心尖J-Valve瓣膜系统。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The J-Valve system (Jie ChengMedical Technologies, Suzhou, China) is designed specifically for transapical transcatheter aortic valve replacement and has three U-shaped graspers. With the unique structure, the J-Valve is suitable for both aortic stenosis and aortic regurgitation. We used the J-Valve system for patients with aortic valve diseases and observed favorable results. METHODS: From January 2018 to August 2019, 23 patients underwent transapical transcatheter valve replacement using the J-Valve system. High-risk patients with diseased peripheral vessels (small diameter, heavily calcified, and tortuous arteries), pure aortic regurgitation, and complex prosthetic valve-in-valve cases were enrolled. Ten patients mainly had aortic stenosis, 11 patients had pure aortic regurgitation, and 2 patients had valve-in-valve aortic valve position. The Society of Thoracic Surgeons and European System for Cardiac Operative Risk Evaluation average preoperative scores were 8.9% and 8.7%, respectively. RESULTS: The technique success rate was 91.3% (21 of 23; 1 patient was referred for open surgery and 1 patient received intraoperative valve-in-valve), and 1 patient died of cardiogenic shock after the procedure (mortality 4.3%, 1 of 22). One patient had stroke postoperatively and recovered well; no cases needed to undergo permanent pacemaker implantation. During the follow-up period, 1 patient died of acute heart attack. No moderate or severe paravalvular leakage was found. CONCLUSIONS: Transcatheter aortic valve replacement surgery with the J-Valve system is effective, even when it is traumatic and requires the transapical route. The applicability of the J-Valve system in pure aortic regurgitation patients is the advantage of this system.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Xue Y, Zhou Q, Li S, et al. Transapical Transcatheter Valve Replacement Using J-Valve for Aortic Valve Diseases. Ann Thorac Surg. 2020. PMID: 33248996. doi:10.1016/j.athoracsur.2020.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。